https://www.selleckchem.com/pr....oducts/lomerizine-hc
The treatment effects on hospitalization for heart failure (hHF) from sodium-glucose cotransporter 2 (SGLT2) inhibitors may vary among type 2 diabetes (T2D) patients depending on whether or not they have established atherosclerotic cardiovascular diseases (ASCVD). We aimed to examine differences in hHF outcomes after dapagliflozin or empagliflozin use between T2D patients with and without a history of established ASCVD. We conducted a retrospective multi-institutional cohort study in Taiwan. We included T2D patients newly receivi
Curtir
Comentario
Compartilhar
